EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 21 (Décembre 2005) Numéro spécial Med Sci (Paris), 21 (2005) 26-29 References
Free Access
Issue
Med Sci (Paris)
Volume 21, Décembre 2005
Métabolisme glucidolipidique et risque cardiovasculaire: Nouvelle approches
Page(s) 26 - 29
Section M/S revues
DOI https://doi.org/10.1051/medsci/20052111s26
Published online 15 November 2005
  1. Hornbostel H. Das angiokeratoma corporis diffusum universale mit kardio-vaso-renalem symptomenkomplex als neuartige thesaurismoseform. Helvetica Medica Acta 1952; 19 : 388–96. [Google Scholar]
  2. MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease : clinical manifestations and impact of the disease in a cohort of 98 hemizygous males.J Med Genet 2001; 38 : 750–60. [Google Scholar]
  3. Whybra C, Kampmann C, Willers I, et al. Anderson-Fabry disease: clinical manifestations of disease in female heterozygotes. J Inherit Metab Dis 2001; 24 : 715–24. [Google Scholar]
  4. Wilcox W, Banikazemi M, Guffon N, et al. Long-term safety and efficacity of enzyme replacement therapy Fabry disease. Am J Hum Genet 2004; 75 : 65–74. [Google Scholar]
  5. Mehta A, Ricci R, Widmer U, et al. Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry outcome survey. Eur J Clin Invest 2004; 34 : 236–42. [Google Scholar]
  6. Valeriani M, Mariotti P, Le Pera D, et al. Functional assessment of A delta and C fibers in patients with Fabry’s disease. Muscle Nerve 2004; 30 : 708–13. [Google Scholar]
  7. Beck M, Whybra C, Wendrick K, et al. Fabry disease in children and adolescent. Contrib Nephrol 2001; 136 : 251–5. [Google Scholar]
  8. Filling-Katz MR, Merrick HF, Fink JK, et al. Carbamazepine in Fabry’s disease: effective analgesia with dose-dependent exacerbation of autonomic dysfunction. Neurology 1989; 39 : 598–600. [Google Scholar]
  9. Hilz MJ, Brys M, Marthol H, et al. Enzyme replacement therapy improves function of C-, Adelta-, and Abeta-nerve fibers in Fabry neuropathy. Neurology 2004; 62 : 1066–72. [Google Scholar]
  10. Luciano CA, Russell JW, Banerjee TK, et al. Physiological characterization of neuropathy in Fabry’s disease. Muscle Nerve 2002; 26 : 622–9. [Google Scholar]
  11. Gomes I, Nora DB, Becker J, et al. Nerve conduction studies, electromyography and sympathetic skin response in Fabry’s disease. J Neurol Sci 2003; 214 : 21–5. [Google Scholar]
  12. Lacomis D, Roeske-Anderson L, Mathie L. Neuropathy and Fabry’s disease. Muscle Nerve 2005; 31 : 102–7. [Google Scholar]
  13. Hozumi I, Nishizawa M, Ariga T, et al. Accumulation of glycosphingolipids in spinal and sympathetic ganglia of a symptomatic heterozygote of Fabry’s disease. J Neurol Sci 1989; 90 : 273–80. [Google Scholar]
  14. De Veber GA, Schwarting GA, et al. Fabry disease : immunocytochemical characterization of neuronal involvement. Ann Neurol 1992; 31 : 409–15. [Google Scholar]
  15. Mitsias P, Levine SR. Cerebrovascular complications of Fabry’s disease. Ann Neurol 1996; 40 : 8–17. [Google Scholar]
  16. Germain DP, Avan P, Chassaing A, et al. Patients affected with Fabry disease have an increased incidence of progressive hearing loss and sudden deafness: an investigation of twenty-two hemizygous male patients. BMC Med Genet 2002; 3 : 10. [Google Scholar]
  17. Cable WJ, Kolodny EH, Adams RD. Fabry disease : impaired autonomic function. Neurology 1982; 32 : 498–502. [Google Scholar]
  18. Giacomini PS, Shannon PT, Clarke JT, et al. Fabry’s disease presenting as stroke in a young female. Can J Neurol Sci 2004; 31 : 112–4. [Google Scholar]
  19. Moore DF, Altarescu G, Braker WC, et al. White matter lesion in Fabry disease occurs in prior selectively hypometabolic and hyperperfused brain regions. Brain Res Bull 2003; 62 : 231–40. [Google Scholar]
  20. Moore DF, Scott LTC, Gladwin MT, et al. Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease. Reversal after enzyme replacement. Circulation 2001; 104 : 1506–12. [Google Scholar]
  21. Boutouyrie P, Laurent S, Laloux B, et al. Non- invasive evaluation of arterial involvement in patients affected with Fabry disease. J Med Genet 2001; 38 : 629–31. [Google Scholar]
  22. DeGraba T, Azhar S, Dignat-George F, et al. Profile of endothelial and leukocyte activation in Fabry patients. Ann Neurol 2000; 47 : 229–33. [Google Scholar]
  23. Hilz MJ, Kolodony EH, Brys M, et al. Reduced cerebral blood flow velocity and impaired cerebral autoregulation in patients with Fabry disease. J Neurol 2004; 251 : 564–70. [Google Scholar]
  24. Crutchfield KE, Patronas NJ, Dambrosia JM, et al. Quantitative analysis of cerebral vasculopathy in patients with Fabry disease. Neurology 1998; 50 : 1746–9. [Google Scholar]
  25. Moore DF, Ye F, Schiffmann R, et al. Increased signals intensity in the pulvinar on T1-weighted images: a pathognomonic MR imaging sign of Fabry disease. Am J Neuroradiol 2003; 62 : 231–40. [Google Scholar]
  26. Takanashi JI, Barkovich J, Dillon WP, et al. T1 hyperintensity in the pulvinar : key imaging feazture for diagnosis of Fabry disease. Am J Neuroradiol 2003; 24 : 916–21. [Google Scholar]
  27. Tedeschi G, Bonavita S, Banerjee TK, et al. Diffuse central neuronal involvement in Fabry disease: a proton MRS imaging study. Neurology 1999; 52 : 1663–7. [Google Scholar]
  28. Moore DF, Altarescu G, Ling GS, et al. Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement. Stroke 2002; 33 : 525–31. [Google Scholar]
  29. Germain DP. La maladie de Fabry en 2004 : l’avènement de la thérapeutique. Rev Prat 2003; 53 : 2215–20. [Google Scholar]
  30. Demuth K, Germain DP. Endothelial markers and homocysteine in patients with classic Fabry disease. Acta Paediatr 2002; 91 : 57–61. [Google Scholar]
  31. Eng CM, Guffon N, Wilcox WR, et al. Safety and efficacy of recombinant human alpha-galactosidase replacement therapy in Fabry’s disease. N Engl J Med 2001; 345 : 9–16. [Google Scholar]
  32. Thurberg BL, Rennke H, Colvin RB, et al. Globotriaosylceramide in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Kidney Int 2002; 62 : 1933–46. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.